Comparative Pharmacology
Head-to-head clinical analysis: EXEM FOAM KIT versus METI DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXEM FOAM KIT versus METI DERM.
EXEM FOAM KIT vs METI-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The active ingredient in EXEM FOAM KIT is diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
METI-DERM contains methylprednisolone aceponate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and prostaglandin synthesis, thereby reducing inflammation, pruritus, and vasodilation.
Apply to affected area twice daily. Exemestane is an aromatase inhibitor; this is a topical formulation.
Apply a thin film topically to affected area once or twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5–6 hours in patients with normal renal function; prolonged in hepatic impairment.
Terminal elimination half-life: 6–8 hours in healthy adults; prolonged to 12–15 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal via biliary elimination (>90% as unchanged drug and metabolites); renal excretion accounts for <10%.
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~35% as metabolites and unchanged drug; minor respiratory elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid